Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [25] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [26] - Total cash inflow for the year amounted to $32 million, driven by public offerings and the exercise of investor warrants [21][22] Business Line Data and Key Metrics Changes - The EVX-01 program, a personalized cancer vaccine, showed a high objective response rate of 75% and a complete response rate of 25% in a two-year phase 2 study [11] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [14] - The EVX-B2 program for gonorrhea retained full global rights, with strong preclinical data indicating significant protection in mouse models [16] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][7] - The autoimmune disease market is being explored, with over 14 million patients affected annually in the U.S. [8] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [34] - There is a commitment to deriving value from both the platform and pipeline assets through partnerships [9] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [8][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [33] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [28] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [62] Other Important Information - The company received recognition from the Galien Foundation for advances in AI in human health [6] - The automated vaccine design module launched in October 2025 enhances the design process, reducing costs and development time [19] Q&A Session Summary Question: Changes to strategy under new CEO - The fundamentals of the company remain strong, with a focus on optimizing value in oncology and infectious disease assets [34] Question: Regulatory submission for EVX-04 - The company is preparing for clinical trials and believes initial proof of concept will attract partner interest [36] Question: Partnering efforts for EVX-01 - The company is seeing interest in the cancer vaccine space, particularly due to strong clinical data and translational insights [46] Question: Application of AI-Immunology in autoimmune diseases - The company is analyzing prevalent autoimmune diseases to determine the best fit for its platform [76]

Core Insights - Evaxion A/S has made significant advancements in its AI-Immunology™ powered vaccine development, particularly in cancer and infectious diseases, showcasing strong data from its lead asset, EVX-01, and successfully out-licensing EVX-B3 to MSD [2][8][20] Business Highlights - The company has validated its technology and strategy through impressive data from EVX-01, which targets multiple neoantigens in cancer vaccines, and the out-licensing of EVX-B3 confirms its capabilities in infectious disease vaccines [2][8] - Evaxion's cash runway has been extended to the second half of 2027, bolstered by a $7.5 million payment from MSD and $7.2 million raised from capital market activities [8][25] - The appointment of Dr. Helen Tayton-Martin as the new CEO is expected to bring over 30 years of experience in biotech M&A and business development [8] Research & Development Update - The phase 2 trial of EVX-01 in advanced melanoma patients showed an Objective Response Rate (ORR) of 75%, with 12 out of 16 patients responding clinically, and 92% of patients still responding at the two-year follow-up [6][10] - Evaxion has expanded its pipeline with EVX-04, targeting non-conventional ERV tumor antigens for acute myeloid leukemia (AML), developed using the AI-Immunology™ platform [12][15] - The company has developed an automated vaccine design module to enhance the efficiency and quality of vaccine development, reducing design time from months to days [17][18] Financial Performance - For Q3 2025, Evaxion reported a net income of $4.6 million, a significant improvement from a net loss of $1.9 million in Q3 2024, driven by revenue from MSD's option exercise [27][28] - Revenue for the quarter was $7.5 million, primarily from the MSD option exercise and included contributions from the Gates Foundation [28] - Research and development expenses were $3.1 million for Q3 2025, compared to $2.6 million in the same period last year, while general and administrative expenses decreased to $1.4 million from $2.1 million [29][30] Equity and Cash Position - As of September 30, 2025, cash and cash equivalents were $10.6 million, up from $6.0 million at the end of 2024, with total equity improving to $16.6 million from a negative equity of $(1.7) million [32][34] - The company has successfully managed its financial strategy, resulting in improved equity and extended cash runway, with an operational cash burn expected to be approximately $14 million in 2025 [34]